Shore Capital Reiterates House Stock Rating for BTG (LON:BTG)

BTG (LON:BTG)‘s stock had its “house stock” rating reissued by research analysts at Shore Capital in a report issued on Tuesday,Digital Look reports.

BTG Stock Performance

The stock has a market cap of £3.26 billion and a price-to-earnings ratio of 29.47. BTG has a twelve month low of GBX 512.50 and a twelve month high of GBX 853.

BTG Company Profile

BTG plc acquires, develops, manufactures, and commercializes pharmaceutical products in the United States, Europe, and internationally. It operates through three segments: Interventional Medicine, Pharmaceuticals, and Licensing. The Interventional Medicine segment offers interventional oncology products and systems, such as beads and TheraSphere for treatment of liver cancer; and GALIL medical system, a cryoablation technology for use in kidney cancer and other indications. This segment also provides interventional vascular products consisting of EKOS system, an ultrasonic catheter drug delivery device used in the treatment of blood clots; Varithena for the treatment of varicose veins; and PneumRx Coil for the treatment of emphysema, a debilitating lung disease.